UOC
ALNY icon

UBS O'Connor’s Alnylam Pharmaceuticals ALNY Stock Holding History

UBS O'Connor’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-29,743
Closed -$1.87M – 404
2016
Q1 		$1.87M Buy
+29,743
New +$1.98M 0.02% 328

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

UBS O'Connor's ALNY Position: Q2 2016 in Review

UBS O'Connor sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2016, closing a stake of 29,743 shares — an estimated $1.87M sold.

UBS O'Connor first reported a position in ALNY in Q1 2016 and held it in 1 quarter. The position peaked at $1.87M in Q1 2016. 249 funds tracked by Wall St. Rank hold ALNY as of Q2 2016.

  • UBS O'Connor reported no remaining Alnylam Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • UBS O'Connor sold 29,743 Alnylam Pharmaceuticals shares in Q2 2016, an estimated $1.87M.
  • UBS O'Connor first reported a position in Alnylam Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • UBS O'Connor's Alnylam Pharmaceuticals position peaked at $1.87M in Q1 2016.
  • 249 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2016.

Based on UBS O'Connor's 13F filing for Q2 2016, filed 12 Aug 2016.